{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:37Z","timestamp":1794008677309,"version":"4.8.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFD106"],"award-info":[{"award-number":["2022CFD106"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Non-small cell lung cancer (NSCLC) remains a significant global health challenge, with high mortality rates and limited treatment options. Tumor vaccines have emerged as a potential therapeutic approach, aiming to stimulate the immune system to specifically target tumor cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study screened 283 clinical trials registered on ClinicalTrials.gov through July 31, 2023. After excluding data that did not meet the inclusion criteria, a total of 108 trials were assessed. Data on registered number, study title, study status, vaccine types, study results, conditions, interventions, outcome measures, sponsor, collaborators, drug target, phases, enrollment, start date, completion date and locations were extracted and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The number of vaccines clinical trials for NSCLC has continued to increase in recent years, the majority of which were conducted in the United States. Most of the clinical trials were at stages ranging from Phase I to Phase II. Peptide-based vaccines accounted for the largest proportion. Others include tumor cell vaccines, DNA\/RNA vaccines, viral vector vaccines, and DC vaccines. Several promising tumor vaccine candidates have shown encouraging results in early-phase clinical trials. However, challenges such as heterogeneity of tumor antigens and immune escape mechanisms still need to be addressed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tumor vaccines represent a promising avenue in the treatment of NSCLC. Ongoing clinical trials are crucial for optimizing vaccine strategies and identifying the most effective combinations. Further research is needed to overcome existing limitations and translate these promising findings into clinical practice, offering new hope for NSCLC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12094-024-03678-z","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T18:03:34Z","timestamp":1724436214000},"page":"1062-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The progress of tumor vaccines clinical trials in non-small cell lung cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Xiaomu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7988-5945","authenticated-orcid":false,"given":"Fang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"issue":"5","key":"3678_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"9","key":"3678_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3206","volume":"22","author":"W Zhang","year":"2020","unstructured":"Zhang W, et al. Survival prediction model for non-small cell lung cancer based on somatic mutations. J Gene Med. 2020;22(9): e3206.","journal-title":"J Gene Med"},{"issue":"6","key":"3678_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11748-017-0752-6","volume":"65","author":"PG Dartevelle","year":"2017","unstructured":"Dartevelle PG, Mitilian D, Fadel E. Extended surgery for T4 lung cancer: a 30 years\u2019 experience. Gen Thorac Cardiovasc Surg. 2017;65(6):321\u20138.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"8","key":"3678_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3678_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","volume":"15","author":"D Uprety","year":"2020","unstructured":"Uprety D, et al. Neoadjuvant Immunotherapy for NSCLC: Current concepts and future approaches. J Thorac Oncol. 2020;15(8):1281\u201397.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3678_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00595-017-1497-7","volume":"48","author":"M Saito","year":"2018","unstructured":"Saito M, et al. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. 2018;48(1):1\u20138.","journal-title":"Surg Today"},{"issue":"9","key":"3678_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","volume":"19","author":"A Harari","year":"2020","unstructured":"Harari A, et al. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19(9):635\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3678_CR8","doi-asserted-by":"publisher","first-page":"e004022","DOI":"10.1136\/jitc-2021-004022","volume":"10","author":"M Xiao","year":"2022","unstructured":"Xiao M, et al. CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy. J Immunother Cancer. 2022;10(5):e004022. https:\/\/doi.org\/10.1136\/jitc-2021-004022.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3678_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","volume":"16","author":"MA Morse","year":"2021","unstructured":"Morse MA, Gwin WR 3rd, Mitchell DA. Vaccine therapies for cancer: then and now. Target Oncol. 2021;16(2):121\u201352.","journal-title":"Target Oncol"},{"issue":"3","key":"3678_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024;24(3):213\u201327.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3678_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.","journal-title":"Mol Cancer"},{"issue":"1","key":"3678_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","volume":"20","author":"X Huang","year":"2021","unstructured":"Huang X, et al. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):50.","journal-title":"Mol Cancer"},{"issue":"2","key":"3678_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2326-6066.CIR-14-0126","volume":"4","author":"OA Ali","year":"2016","unstructured":"Ali OA, et al. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 2016;4(2):95\u2013100.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"3678_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/JLB.5BT0420-585RR","volume":"108","author":"S Roy","year":"2020","unstructured":"Roy S, et al. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. J Leukoc Biol. 2020;108(4):1455\u201389.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"3678_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13025","volume":"54","author":"W Liu","year":"2021","unstructured":"Liu W, et al. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54(5): e13025.","journal-title":"Cell Prolif"},{"issue":"12","key":"3678_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","volume":"55","author":"PF Brunsvig","year":"2006","unstructured":"Brunsvig PF, et al. Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006;55(12):1553\u201364.","journal-title":"Cancer Immunol Immunother"},{"key":"3678_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572172","volume":"11","author":"PF Brunsvig","year":"2020","unstructured":"Brunsvig PF, et al. Long-term outcomes of a phase i study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer. Front Immunol. 2020;11: 572172.","journal-title":"Front Immunol"},{"key":"3678_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013377.pub2","author":"M Cortes-Jofre","year":"2024","unstructured":"Cortes-Jofre M, et al. Therapeutic vaccines for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2024. https:\/\/doi.org\/10.1002\/14651858.CD013377.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"3678_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","volume":"34","author":"B Besse","year":"2023","unstructured":"Besse B, et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023;34(10):920\u201333.","journal-title":"Ann Oncol"},{"issue":"17","key":"3678_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, et al. Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells. 2023;12(17):2159.","journal-title":"Cells"},{"issue":"15 Pt 2","key":"3678_CR21","doi-asserted-by":"publisher","first-page":"s4652","DOI":"10.1158\/1078-0432.CCR-07-0213","volume":"13","author":"R Sangha","year":"2007","unstructured":"Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res. 2007;13(15 Pt 2):s4652\u20134.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3678_CR22","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","volume":"137","author":"C Butts","year":"2011","unstructured":"Butts C, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137(9):1337\u201342.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3678_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59\u201368.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3678_CR24","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1586\/14760584.2015.1079488","volume":"14","author":"T Crombet Ramos","year":"2015","unstructured":"Crombet Ramos T, et al. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(10):1303\u201311.","journal-title":"Expert Rev Vaccines"},{"key":"3678_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fimmu.2017.00269","volume":"8","author":"D Saavedra","year":"2017","unstructured":"Saavedra D, Crombet T. CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol. 2017;8:269.","journal-title":"Front Immunol"},{"issue":"15","key":"3678_CR26","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1158\/1078-0432.CCR-15-0855","volume":"22","author":"PC Rodriguez","year":"2016","unstructured":"Rodriguez PC, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22(15):3782\u201390.","journal-title":"Clin Cancer Res"},{"key":"3678_CR27","doi-asserted-by":"publisher","first-page":"1287902","DOI":"10.3389\/fonc.2023.1287902","volume":"13","author":"RA Ortiz Carrodeguas","year":"2023","unstructured":"Ortiz Carrodeguas RA, et al. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics. Front Oncol. 2023;13:1287902.","journal-title":"Front Oncol"},{"issue":"4","key":"3678_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/14712598.2016.1157579","volume":"16","author":"MR Gabri","year":"2016","unstructured":"Gabri MR, et al. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert Opin Biol Ther. 2016;16(4):573\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"6382","key":"3678_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, Tureci O. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355\u201360.","journal-title":"Science"},{"issue":"1","key":"3678_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4161\/hv.26568","volume":"10","author":"S Srivatsan","year":"2014","unstructured":"Srivatsan S, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother. 2014;10(1):52\u201363.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3678_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/JTO.0b013e3181fb5c22","volume":"6","author":"EA Hirschowitz","year":"2011","unstructured":"Hirschowitz EA, et al. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. J Thorac Oncol. 2011;6(1):169\u201373.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3678_CR32","first-page":"431","volume":"16","author":"R Gollard","year":"2023","unstructured":"Gollard R, et al. Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report. Case Rep Oncol. 2023;16(1):431\u20137.","journal-title":"Case Rep Oncol"},{"issue":"15_suppl","key":"3678_CR33","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1200\/JCO.2019.37.15_suppl.9109","volume":"37","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern D, et al. Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure. J Clinic Oncol. 2019;37(15_suppl):9109.","journal-title":"J Clinic Oncol"},{"issue":"16","key":"3678_CR34","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone G, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321\u20139.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3678_CR35","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-018-2236-7","volume":"67","author":"JE Gray","year":"2018","unstructured":"Gray JE, et al. A phase I\/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunol Immunother. 2018;67(12):1853\u201362.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3678_CR36","doi-asserted-by":"publisher","first-page":"2198467","DOI":"10.1080\/21645515.2023.2198467","volume":"19","author":"RO Dillman","year":"2023","unstructured":"Dillman RO, Nistor GI, Keirstead HS. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. Hum Vaccin Immunother. 2023;19(1):2198467.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3678_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-017-0306-6","volume":"5","author":"RE Sanborn","year":"2017","unstructured":"Sanborn RE, et al. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2017;5(1):103.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3678_CR38","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1586\/erv.09.108","volume":"8","author":"G Tosti","year":"2009","unstructured":"Tosti G, et al. HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. Expert Rev Vaccines. 2009;8(11):1513\u201326.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"3678_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","volume":"38","author":"A Lopes","year":"2019","unstructured":"Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38(1):146.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"3678_CR40","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","volume":"10","author":"B Yang","year":"2014","unstructured":"Yang B, et al. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153\u201364.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"3678_CR41","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ymthe.2006.01.013","volume":"13","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther. 2006;13(6):1185\u201391.","journal-title":"Mol Ther"},{"issue":"3","key":"3678_CR42","first-page":"180","volume":"10","author":"CJ Ercole","year":"1992","unstructured":"Ercole CJ, Oliveira Filho EK. Microsurgical vasovasostomy under local anesthesia: an outpatient setting. Semin Urol. 1992;10(3):180\u20133.","journal-title":"Semin Urol"},{"issue":"2","key":"3678_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1348-0421.2006.tb03773.x","volume":"50","author":"HA Yoon","year":"2006","unstructured":"Yoon HA, et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol. 2006;50(2):83\u201392.","journal-title":"Microbiol Immunol"},{"issue":"1","key":"3678_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.","journal-title":"Mol Cancer"},{"key":"3678_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923647","volume":"13","author":"LJ Duan","year":"2022","unstructured":"Duan LJ, et al. Potentialities and challenges of mRNA vaccine in cancer immunotherapy. Front Immunol. 2022;13: 923647.","journal-title":"Front Immunol"},{"key":"3678_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S35570","volume":"2","author":"DK Krishnadas","year":"2013","unstructured":"Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. Immunotargets Ther. 2013;2:11\u20139.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"3678_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou A, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7(1):38.","journal-title":"J Immunother Cancer"},{"key":"3678_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102405","volume":"107","author":"J Wei","year":"2022","unstructured":"Wei J, Hui AM. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines. Cancer Treat Rev. 2022;107: 102405.","journal-title":"Cancer Treat Rev"},{"issue":"7963","key":"3678_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"1","key":"3678_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","volume":"7","author":"ZS Guo","year":"2019","unstructured":"Guo ZS, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3678_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2217\/imt-2016-0015","volume":"8","author":"E Arriola","year":"2016","unstructured":"Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy. 2016;8(5):511\u20139.","journal-title":"Immunotherapy"},{"issue":"9","key":"3678_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.21037\/atm.2016.04.16","volume":"4","author":"RA de Mello","year":"2016","unstructured":"de Mello RA. TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer? Ann Transl Med. 2016;4(9):185.","journal-title":"Ann Transl Med"},{"issue":"16","key":"3678_CR53","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, et al. Phase I Trial of Intratumoral Injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res. 2017;23(16):4556\u201368.","journal-title":"Clin Cancer Res"},{"key":"3678_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","volume":"348","author":"S Balan","year":"2019","unstructured":"Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1\u201368.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"3","key":"3678_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092380","volume":"9","author":"D Dissanayake","year":"2014","unstructured":"Dissanayake D, et al. Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant. PLoS ONE. 2014;9(3): e92380.","journal-title":"PLoS ONE"},{"issue":"1","key":"3678_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021;6(1):26.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"3678_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PPO.0b013e318233e6b4","volume":"17","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Giaccone G. Lung cancer vaccines. Cancer J. 2011;17(5):302\u20138.","journal-title":"Cancer J"},{"key":"3678_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","volume":"119","author":"C Guo","year":"2013","unstructured":"Guo C, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421\u201375.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"3678_CR59","doi-asserted-by":"publisher","first-page":"874","DOI":"10.7150\/jca.67189","volume":"14","author":"YI Flores Vega","year":"2023","unstructured":"Flores Vega YI, et al. Survival of NSCLC patients treated with cimavax-EGF as switch maintenance in the real-world scenario. J Cancer. 2023;14(5):874\u20139.","journal-title":"J Cancer"},{"key":"3678_CR60","doi-asserted-by":"publisher","first-page":"4325874","DOI":"10.1155\/2018\/4325874","volume":"2018","author":"RY Pan","year":"2018","unstructured":"Pan RY, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874.","journal-title":"J Immunol Res"},{"issue":"12","key":"3678_CR61","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","volume":"11","author":"JL Pujol","year":"2016","unstructured":"Pujol JL, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. J Thorac Oncol. 2016;11(12):2208\u201317.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3678_CR62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","volume":"17","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17(5):343\u201350.","journal-title":"Cancer J"},{"key":"3678_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696791","volume":"12","author":"AJ Stephens","year":"2021","unstructured":"Stephens AJ, Burgess-Brown NA, Jiang S. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines. Front Immunol. 2021;12: 696791.","journal-title":"Front Immunol"},{"issue":"3","key":"3678_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/vaccines2030515","volume":"2","author":"W Li","year":"2014","unstructured":"Li W, et al. Peptide vaccine: progress and challenges. Vaccines (Basel). 2014;2(3):515\u201336.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"3678_CR65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","volume":"39","author":"BP Keenan","year":"2012","unstructured":"Keenan BP, Jaffee EM. Whole cell vaccines\u2013past progress and future strategies. Semin Oncol. 2012;39(3):276\u201386.","journal-title":"Semin Oncol"},{"issue":"8","key":"3678_CR66","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/cgt.2009.15","volume":"16","author":"J Nemunaitis","year":"2009","unstructured":"Nemunaitis J, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16(8):620\u20134.","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"3678_CR67","first-page":"2665","volume":"20","author":"B Bodey","year":"2000","unstructured":"Bodey B, et al. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000;20(4):2665\u201376.","journal-title":"Anticancer Res"},{"issue":"3","key":"3678_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3816\/CLC.2003.n.027","volume":"5","author":"J Nemunaitis","year":"2003","unstructured":"Nemunaitis J, Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer. Clin Lung Cancer. 2003;5(3):148\u201357.","journal-title":"Clin Lung Cancer"},{"key":"3678_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pharmthera.2017.02.016","volume":"174","author":"CD Zahm","year":"2017","unstructured":"Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacol Ther. 2017;174:27\u201342.","journal-title":"Pharmacol Ther"},{"issue":"23\u201324","key":"3678_CR70","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1016\/S0264-410X(02)00238-4","volume":"20","author":"Y Kojima","year":"2002","unstructured":"Kojima Y, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine. 2002;20(23\u201324):2857\u201365.","journal-title":"Vaccine"},{"key":"3678_CR71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21775\/cimb.022.079","volume":"22","author":"AI Myhr","year":"2017","unstructured":"Myhr AI. DNA vaccines: regulatory considerations and safety aspects. Curr Issues Mol Biol. 2017;22:79\u201388.","journal-title":"Curr Issues Mol Biol"},{"issue":"16","key":"3678_CR72","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1089\/10430349950016762","volume":"10","author":"WZ Zhou","year":"1999","unstructured":"Zhou WZ, et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther. 1999;10(16):2719\u201324.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"3678_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023;13(8): e1384.","journal-title":"Clin Transl Med"},{"issue":"1","key":"3678_CR74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2012.202","volume":"21","author":"C Pollard","year":"2013","unstructured":"Pollard C, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251\u20139.","journal-title":"Mol Ther"},{"issue":"21","key":"3678_CR75","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1200\/JCO.2012.42.3293","volume":"30","author":"K Kalinsky","year":"2012","unstructured":"Kalinsky K, Hershman DL. Cracking open window of opportunity trials. J Clin Oncol. 2012;30(21):2573\u20135.","journal-title":"J Clin Oncol"},{"key":"3678_CR76","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2018.10.008","volume":"292","author":"R Zhang","year":"2018","unstructured":"Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018;292:256\u201376.","journal-title":"J Control Release"},{"issue":"2","key":"3678_CR77","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/viro.2000.0203","volume":"268","author":"R Drillien","year":"2000","unstructured":"Drillien R, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology. 2000;268(2):471\u201381.","journal-title":"Virology"},{"issue":"15","key":"3678_CR78","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1158\/1078-0432.CCR-05-0670","volume":"11","author":"S Yang","year":"2005","unstructured":"Yang S, Tsang KY, Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res. 2005;11(15):5603\u201315.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3678_CR79","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624\u201341.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"3678_CR80","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","volume":"17","author":"C Larocca","year":"2011","unstructured":"Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J. 2011;17(5):359\u201371.","journal-title":"Cancer J"},{"issue":"1","key":"3678_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","volume":"5","author":"C Tosch","year":"2017","unstructured":"Tosch C, et al. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J Immunother Cancer. 2017;5(1):70.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3678_CR82","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","volume":"15","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom K. Viral vectors in gene therapy: Where do we stand in 2023? Viruses. 2023;15(3):698. https:\/\/doi.org\/10.3390\/v15030698.","journal-title":"Viruses"},{"issue":"7","key":"3678_CR83","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257\u201367.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3678_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1586\/1744666X.2015.987663","volume":"11","author":"N Mody","year":"2015","unstructured":"Mody N, et al. Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 2015;11(2):213\u201332.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3678_CR85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nm1039","volume":"10","author":"CG Figdor","year":"2004","unstructured":"Figdor CG, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10(5):475\u201380.","journal-title":"Nat Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03678-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03678-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03678-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:14:48Z","timestamp":1742192088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03678-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03678-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}